Zydus reaches patent settlement on Qudexy

13 January 2017

Indian drugmaker Cadila Healthcare and its US subsidiary Zydus Pharmacetuicals today announced that they have finalized an agreement with privately-held US generics firm Upsher-Smith Laboratories, to settle all outstanding patent litigation related to Qudexy XR (topiramate) extended-release capsules.

Under the terms of the agreement, Upsher-Smith grants Zydus a license to market Zydus’ generic version of Qudexy XR beginning on March 19, 2020, or earlier under certain circumstances. Other terms of the settlement were not disclosed.

US healthcare giant Johnson & Johnson (NYSE: JNJ) markets topiramate, a now off-patent anti-epileptic drug, as Topamax, and it is an ingredient in Vivus’ (Nasdaq: VVUS) Qsymia (topiramate/phentermine), a weight-loss drug.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK